Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1971 1
1986 1
1994 1
1998 1
2002 1
2009 3
2011 2
2012 2
2013 3
2014 1
2015 1
2016 1
2017 2
2018 3
2019 6
2020 2
2021 6
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63-74). ...
FINDINGS: Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n …
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Carrier M, et al. N Engl J Med. 2019 Feb 21;380(8):711-719. doi: 10.1056/NEJMoa1814468. Epub 2018 Dec 4. N Engl J Med. 2019. PMID: 30511879 Clinical Trial.
LITERATURE ABSTRACTS.
[No authors listed] [No authors listed] J Texture Stud. 1971 Dec;2(4):502-509. doi: 10.1111/j.1745-4603.1971.tb00598.x. J Texture Stud. 1971. PMID: 28370130
General Principles: 'Statistical Aspect of the Correlation Between Objective and Subjective Measurements of Meat Tenderness', by M. C. Gacula, Jr., J. B. Reaume, K. J. Morgan, and R. L. Luckett 1. General Principles: 'Texture of Semi-Solid Foods: Sensory and Physical Corre …
General Principles: 'Statistical Aspect of the Correlation Between Objective and Subjective Measurements of Meat Tenderness', by M. C. Gacul …
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators. Motzer RJ, et al. J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13. J Clin Oncol. 2017. PMID: 28902533 Free PMC article. Clinical Trial.
To address toxicity attrition, the 800-mg starting dose was lowered to 600 mg, and the primary end point analysis was changed to disease-free survival (DFS) for pazopanib 600 mg versus placebo (n = 1,135). Primary analysis was performed after 350 DFS events in the intent-t …
To address toxicity attrition, the 800-mg starting dose was lowered to 600 mg, and the primary end point analysis was changed to disease-fre …
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA. Sartor O, et al. Eur Urol. 2023 Aug;84(2):156-163. doi: 10.1016/j.eururo.2023.04.024. Epub 2023 May 12. Eur Urol. 2023. PMID: 37179241 Free PMC article. Clinical Trial.
Predicting Intracerebral Hemorrhage Growth With the Spot Sign: The Effect of Onset-to-Scan Time.
Dowlatshahi D, Brouwers HB, Demchuk AM, Hill MD, Aviv RI, Ufholz LA, Reaume M, Wintermark M, Hemphill JC 3rd, Murai Y, Wang Y, Zhao X, Wang Y, Li N, Sorimachi T, Matsumae M, Steiner T, Rizos T, Greenberg SM, Romero JM, Rosand J, Goldstein JN, Sharma M. Dowlatshahi D, et al. Stroke. 2016 Mar;47(3):695-700. doi: 10.1161/STROKEAHA.115.012012. Epub 2016 Feb 4. Stroke. 2016. PMID: 26846857 Free PMC article. Review.
Physical Morbidity and Mental Health Care Among Young People.
Reaume SV, Luther AWM, Ferro MA. Reaume SV, et al. J Adolesc Health. 2021 Mar;68(3):540-547. doi: 10.1016/j.jadohealth.2020.06.040. Epub 2020 Aug 5. J Adolesc Health. 2021. PMID: 32768329
PURPOSE: This epidemiological study examined associations between morbidity status and mental health care use among young people. METHODS: Data come from individuals aged 15-29 years (n = 5,630) in the Canadian Community Health Survey-Mental Health (2012). ...
PURPOSE: This epidemiological study examined associations between morbidity status and mental health care use among young people. METHODS: D …
Mental health of siblings of children with physical illness or physical-mental comorbidity.
Qureshi SA, Reaume SV, Bedard C, Ferro MA. Qureshi SA, et al. Child Care Health Dev. 2023 May;49(3):456-463. doi: 10.1111/cch.13061. Epub 2022 Sep 19. Child Care Health Dev. 2023. PMID: 36098996
METHODS: The sample included children aged 2 to 16 years with a chronic PI and their aged-matched healthy siblings (n = 169 dyads). Physical-mental comorbidity (PM) was present if children screened positive for 1 mental illness on the Mini International Neuropsychiatric In …
METHODS: The sample included children aged 2 to 16 years with a chronic PI and their aged-matched healthy siblings (n = 169 dyads). P …
39 results